Puma Biotechnology
PBYI
184 hedge funds and large institutions have $6.37B invested in Puma Biotechnology in 2014 Q3 according to their latest regulatory filings, with 67 funds opening new positions, 42 increasing their positions, 70 reducing their positions, and 20 closing their positions.
278% more capital invested
Capital invested by funds: $1.69B → $6.37B (+$4.68B)
235% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 20
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
33% more funds holding
Funds holding: 138 → 184 (+46)
3.83% more ownership
Funds ownership: 84.76% → 88.59% (+3.8%)
4% more call options, than puts
Call options by funds: $99.2M | Put options by funds: $95.4M
40% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 70
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$377M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$261M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$67.6M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$61.6M |
| 5 |
OH
Orbis Holdings
Hamilton,
Bermuda
|
+$44.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$173M |
| 2 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$51M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$49.2M |
| 4 |
CCI
Columbus Circle Investors
|
-$48M |
| 5 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$42.3M |
PBYI Hedge Fund Activity: Q3 2014 in Review
184 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q3 2014, worth a combined $6.37B — up 278% from $1.69B a quarter earlier.
Buyers outnumbered sellers: 67 funds opened new PBYI positions and 20 closed out — a net gain of 47 holders — while 42 added to existing stakes and 70 trimmed.
The largest buyer was Capital Research Global Investors, opening a new position worth an estimated $377M. The largest seller was Lord, Abbett & Co, cutting an estimated $173M.
- 184 institutional investors held Puma Biotechnology (PBYI) as of Q3 2014, up from 138 in Q2 2014.
- Funds reported $6.37B of Puma Biotechnology stock for Q3 2014, up 278% quarter-over-quarter.
- 67 funds opened new Puma Biotechnology positions in Q3 2014 and 20 closed out, a net change of +47 holders.
- The largest Puma Biotechnology buyer in Q3 2014 was Capital Research Global Investors, an estimated $377M added.
- The largest Puma Biotechnology seller in Q3 2014 was Lord, Abbett & Co, an estimated $173M sold.
Based on aggregated 13F filings for Q3 2014.